Novo Nordisk takes on Lilly with newly approved diabetes drug

Novo Nordisk's newly approved Ozempic will compete directly with Eli Lilly and Co.'s Trulicity in the diabetes drug market.  -More- …
Read the full story: BIO SmartBrief